Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Attard

Showing results (61-70 of 76) with videos related to

Pageof 8
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 3, 2023
Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trialK N Chi, S Sandhu, M R Smith, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 26, 2013
Poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of advanced germline BRCA2 mutant prostate cancerS K Sandhu, A Omlin, L Hylands, et al.
Prostate Cancer and Prostatic Diseases|February 24, 2010
The identification of chromosomal translocation, t(4;6)(q22;q15), in prostate cancerL Shan, L Ambroisine, J Clark, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 20, 2025
Local and locoregional prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upJ Walz, G Attard, A Bjartell, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 26, 2017
Precision, complexity and stigma in advanced prostate cancer terminology: it is time to move away from 'castration-resistant' prostate cancerC J Pezaro, A Omlin, K Mastris, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 10, 2023
Transcriptomic and clinical heterogeneity of metastatic disease timing within metastatic castration-sensitive prostate cancerP A Sutera, A C Shetty, A Hakansson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 30, 2017
Intratumoural evolutionary landscape of high-risk prostate cancer: the PROGENY study of genomic and immune parametersM Linch, G Goh, C Hiley, et al.
Nature Communications|September 7, 2021
Single-cell ATAC and RNA sequencing reveal pre-existing and persistent cells associated with prostate cancer relapseS Taavitsainen, N Engedal, S Cao, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 12, 2026
Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upK Fizazi, G Attard, A A Azad, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 5, 2017
Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker studyV Conteduca, D Wetterskog, M T A Sharabiani, et al.
Pageof 8

Showing results (61-70 of 76) with videos related to

Sort By:
Pageof 8
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 3, 2023
Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trialK N Chi, S Sandhu, M R Smith, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 26, 2013
Poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of advanced germline BRCA2 mutant prostate cancerS K Sandhu, A Omlin, L Hylands, et al.
Prostate Cancer and Prostatic Diseases|February 24, 2010
The identification of chromosomal translocation, t(4;6)(q22;q15), in prostate cancerL Shan, L Ambroisine, J Clark, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 20, 2025
Local and locoregional prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upJ Walz, G Attard, A Bjartell, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 26, 2017
Precision, complexity and stigma in advanced prostate cancer terminology: it is time to move away from 'castration-resistant' prostate cancerC J Pezaro, A Omlin, K Mastris, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 10, 2023
Transcriptomic and clinical heterogeneity of metastatic disease timing within metastatic castration-sensitive prostate cancerP A Sutera, A C Shetty, A Hakansson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 30, 2017
Intratumoural evolutionary landscape of high-risk prostate cancer: the PROGENY study of genomic and immune parametersM Linch, G Goh, C Hiley, et al.
Nature Communications|September 7, 2021
Single-cell ATAC and RNA sequencing reveal pre-existing and persistent cells associated with prostate cancer relapseS Taavitsainen, N Engedal, S Cao, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 12, 2026
Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upK Fizazi, G Attard, A A Azad, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 5, 2017
Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker studyV Conteduca, D Wetterskog, M T A Sharabiani, et al.
Pageof 8